Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

MDS Unit

2 abstracts

Abstract
Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.
Org: Marien Hospital Düsseldorf, Cancer Center IRCCS Humanitas Research Hospital, IRCSS Azienda Ospedaliera Universitaria di Bologna, MDS Unit, Service d'Hématologie Séniors,
Abstract
A phase 2/3 trial of oral azacitidine (Oral-AZA) in patients (pts) with low- or intermediate-risk myelodysplastic syndromes (MDS).
Org: MD Anderson Cancer Center, MDS Unit, Bristol Myers Squibb, Sylvester Comprehensive Cancer Center, Miami, FL, Marien Hospital Düsseldorf,